Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement
Author:
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Link
https://link.springer.com/content/pdf/10.1007/s10198-023-01584-9.pdf
Reference52 articles.
1. Fojo, T., Mailankody, S., Lo, A.: Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 140(12), 1225–1236 (2014). https://doi.org/10.1001/jamaoto.2014.1570
2. Kumar, H., Fojo, T., Mailankody, S.: An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. JAMA Oncol. 2(9), 1238–1240 (2016). https://doi.org/10.1001/jamaoncol.2016.0931
3. Shin, G., Kwon, H.Y., Bae, S.: For whom the price escalates: high price and uncertain value of cancer drugs. Int J Environ Res Public Health. 19(7), 4204 (2022). https://doi.org/10.3390/ijerph19074204
4. Kemp, R., Prasad, V.: Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 15(1), 134 (2017). https://doi.org/10.1186/s12916-017-0902-9
5. Chen, E.Y., Haslam, A., Prasad, V.: FDA acceptance of surrogate end points for cancer drug approval: 1992–2019. JAMA Intern Med. 180(6), 912–914 (2020). https://doi.org/10.1001/jamainternmed.2020.1097
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of competition on reimbursement decisions for cancer drugs in China: an observational study;The Lancet Regional Health - Western Pacific;2024-09
2. Factors influencing the reimbursement of cancer drugs in Europe: A scoping review;Journal of Evaluation in Clinical Practice;2024-07-03
3. [Translated article] Characteristics, clinical benefit, and reimbursement of new authorisations for oncohaematology drugs in Spain between 2017 and 2020;Farmacia Hospitalaria;2024-07
4. Características, beneficio clínico y financiación de las nuevas autorizaciones de fármacos oncohematológicos en España entre 2017 y 2020;Farmacia Hospitalaria;2024-05
5. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS;Journal of Cancer Research and Clinical Oncology;2024-03-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3